X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mk2206 (24) 24
oncology (17) 17
index medicus (16) 16
humans (15) 15
apoptosis (11) 11
cell line, tumor (11) 11
akt (10) 10
heterocyclic compounds, 3-ring - pharmacology (10) 10
proto-oncogene proteins c-akt - metabolism (10) 10
activation (9) 9
proto-oncogene proteins c-akt - antagonists & inhibitors (9) 9
cancer (8) 8
animals (6) 6
antineoplastic agents - pharmacology (6) 6
cancer research (6) 6
cell proliferation (6) 6
cell proliferation - drug effects (6) 6
phosphorylation (6) 6
studies (6) 6
blotting, western (5) 5
cancer therapies (5) 5
cellular signal transduction (5) 5
female (5) 5
kinases (5) 5
mk-2206 (5) 5
pathway (5) 5
research (5) 5
signal transduction (5) 5
signal transduction - drug effects (5) 5
akt inhibitor (4) 4
analysis (4) 4
apoptosis - drug effects (4) 4
article (4) 4
breast-cancer (4) 4
chemotherapy (4) 4
expression (4) 4
hepatocellular carcinoma (4) 4
male (4) 4
mice, inbred balb c (4) 4
protein kinase inhibitors - pharmacology (4) 4
proteins (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
carcinoma (3) 3
carcinoma, hepatocellular - drug therapy (3) 3
carcinoma, hepatocellular - pathology (3) 3
care and treatment (3) 3
cell growth (3) 3
cells (3) 3
clinical trials (3) 3
drug resistance (3) 3
drug synergism (3) 3
gene expression (3) 3
gene expression regulation, neoplastic (3) 3
genetic aspects (3) 3
genetics (3) 3
health aspects (3) 3
liver cancer (3) 3
liver neoplasms - drug therapy (3) 3
liver neoplasms - pathology (3) 3
medical prognosis (3) 3
mice (3) 3
physiological aspects (3) 3
resistance (3) 3
sorafenib (3) 3
tumors (3) 3
xenograft model antitumor assays (3) 3
adult (2) 2
aged (2) 2
akt inhibition (2) 2
akt pathway (2) 2
amplification (2) 2
antineoplastic agents - therapeutic use (2) 2
articles (2) 2
biomarkers (2) 2
biomarkers, tumor - metabolism (2) 2
biomedicine (2) 2
biotechnology (2) 2
brain cancer (2) 2
brain neoplasms - metabolism (2) 2
brain tumors (2) 2
breast neoplasms (2) 2
cancer-cells (2) 2
carcinoma, hepatocellular - metabolism (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
cell movement (2) 2
cell movement - drug effects (2) 2
cell survival - drug effects (2) 2
chemoresistance (2) 2
cisplatin (2) 2
cisplatin - pharmacology (2) 2
cytoskeleton (2) 2
dna methylation (2) 2
down-regulation (2) 2
drug resistance, neoplasm - drug effects (2) 2
epidermal growth factor (2) 2
everolimus (2) 2
f-actin (2) 2
gene expression profiling (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chinese Journal of Pharmacology and Toxicology, ISSN 1000-3002, 08/2017, Volume 31, Issue 8, pp. 793 - 799
Journal Article
Chinese Journal of Cancer Prevention and Treatment, ISSN 1673-5269, 07/2015, Volume 22, Issue 13, pp. 998 - 1003
Journal Article
by Li, Y and Chen, D and Hao, FY and Zhang, KJ
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, ISSN 1128-3602, 06/2016, Volume 20, Issue 12, pp. 2581 - 2587
OBJECTIVE: We have recently reported that therapies targeting TGF-beta 1 signaling were effective to prevent the anaplastic thyroid cancer (ATC) cell growth,... 
ACTIVATION | TGF-BETA | INHIBITOR MK-2206 | KINASE | PHASE-II | TGF-D | SYNERGIZES | TRIAL | Anaplastic thyroid cancer | Phosphatidylinositol 3-kinase (PI3K)/AKT | MK2206 | PHARMACOLOGY & PHARMACY | EXPRESSION | CARCINOMA
Journal Article
Journal Article
Cardiovascular Research, ISSN 0008-6363, 2012, Volume 95, Issue 3, pp. 290 - 299
Cardiotoxic side effects of anthracyclines, the most widely used anticancer drugs, are well documented, while mechanisms involved are not fully elucidated. The... 
Adenosine 5'-monopnophosphate-activated protein kinase | MK2206 | Anthracyclines | Cardiotoxicity | Cardiac energetics | Cardiac signalling | MAMMALIAN TARGET | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED PROTEIN-KINASE | OBESE RATS | DNA-DAMAGE | INDUCED CARDIOMYOPATHY | Adenosine 5-monopnophosphate-activated protein kinase | PERFUSED RAT-HEART | AKT ACTIVITY | INDUCED CARDIOTOXICITY | RESVERATROL PREVENTS | GROWTH-FACTORS | AMP-Activated Protein Kinases - metabolism | Phosphorylation | Antibiotics, Antineoplastic - toxicity | Rats, Wistar | TOR Serine-Threonine Kinases - metabolism | Male | Dose-Response Relationship, Drug | Myocytes, Cardiac - enzymology | Time Factors | Heart Diseases - chemically induced | Proto-Oncogene Proteins c-akt - metabolism | Disease Models, Animal | Heart Diseases - physiopathology | AMP-Activated Protein Kinases - antagonists & inhibitors | Rats | Heart Diseases - enzymology | Doxorubicin - toxicity | Myocytes, Cardiac - pathology | Animals | Myocytes, Cardiac - drug effects | Signal Transduction - drug effects | Protein Kinase Inhibitors - toxicity | DNA Damage | Enzyme Activation | Oxidative Stress - drug effects | Acetyl-CoA Carboxylase - metabolism | Energy Metabolism - drug effects | Heart Diseases - genetics | Heart Diseases - pathology | Mitogen-Activated Protein Kinases - metabolism | Index Medicus | Life Sciences | Biochemistry, Molecular Biology
Journal Article
International Journal of Cancer, ISSN 0020-7136, 07/2013, Volume 133, Issue 1, pp. 21 - 30
Journal Article
Cancer Research, ISSN 0008-5472, 09/2013, Volume 73, Issue 17, pp. 5532 - 5543
Intrinsic resistance to agents targeting phosphoinositide 3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The... 
E3 LIGASE | CELLS | OXIDATIVE STRESS | ACTIVATION | ANTIOXIDANT RESPONSE ELEMENT | NRF2 | ONCOLOGY | NF-E2-RELATED FACTOR-2 | ENZYME GENES | THIOREDOXIN REDUCTASE | NF-KAPPA-B | Lung Neoplasms - drug therapy | RNA, Small Interfering - genetics | Cell Proliferation | Luciferases - metabolism | Reactive Oxygen Species - metabolism | Glutathione - metabolism | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Lung Neoplasms - pathology | Intracellular Signaling Peptides and Proteins - metabolism | Immunoenzyme Techniques | Proto-Oncogene Proteins c-akt - genetics | Genes, Lethal | NF-E2-Related Factor 2 - genetics | Antirheumatic Agents - pharmacology | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | Intracellular Signaling Peptides and Proteins - genetics | Kelch-Like ECH-Associated Protein 1 | Real-Time Polymerase Chain Reaction | Auranofin - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | RNA, Messenger - genetics | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Animals | NF-E2-Related Factor 2 - metabolism | Fluorescent Antibody Technique | Thioredoxin Reductase 1 - antagonists & inhibitors | Mice | Thioredoxin Reductase 1 - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Microscopy, Fluorescence | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Apoptosis | Thioredoxin Reductase 1 - metabolism | Index Medicus | MK2206 | KEAP1 | AKT | Synthetic lethality | TXNRD1
Journal Article
Cancer Cell International, ISSN 1475-2867, 02/2015, Volume 15, Issue 1, pp. 13 - 13
Introduction: Cholangiocarcinoma (CCA) is an aggressive disease with limited effective treatment options. The PI3K/Akt/mTOR pathway represents an attractive... 
PI3K/mTOR/AKT | MK2206 | Cholangiocarcinoma | Apoptosis | INTRAHEPATIC CHOLANGIOCARCINOMA | ACTIVATION | MARKER | CANCER | LINES | IN-VITRO | ONCOLOGY | MK-2206 | RECURRENCE | GROWTH SUPPRESSION | EXPRESSION | Physiological aspects | Genetic aspects | Research | Protein kinases
Journal Article
Cancer Letters, ISSN 0304-3835, 2017, Volume 403, pp. 119 - 127
Abstract EGFR amplification and mutations are the most common oncogenic events in GBM. EGFR overexpression correlates with GBM invasion, but the underlying... 
Hematology, Oncology and Palliative Medicine | EGFR pathway | Cytoskeleton | MK2206 | Glioblastoma | AJAP1 | PHOSPHOINOSITIDE 3-KINASE PATHWAY | EGFR KINASE INHIBITORS | CANCER-CELLS | F-ACTIN | AKT | GROWTH-FACTOR RECEPTOR | ONCOLOGY | GENE-EXPRESSION | RESISTANCE | UP-REGULATION | Receptor, Epidermal Growth Factor - genetics | Cell Adhesion Molecules - genetics | Heterocyclic Compounds, 3-Ring - pharmacology | Epigenesis, Genetic | Humans | Gene Expression Regulation, Neoplastic | Databases, Genetic | Gene Expression Profiling | Brain Neoplasms - metabolism | DNA Methylation | Receptor, Epidermal Growth Factor - metabolism | Transfection | RNA Interference | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-akt - metabolism | Phosphatidylinositol 3-Kinase - metabolism | Promoter Regions, Genetic | Enhancer of Zeste Homolog 2 Protein - metabolism | Actin Cytoskeleton - metabolism | Signal Transduction | Neoplasm Invasiveness | Computational Biology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Cell Adhesion Molecules - metabolism | Xenograft Model Antitumor Assays | Cell Movement - drug effects | Animals | Mice, Nude | Cell Line, Tumor | Cell Proliferation - drug effects | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Epigenetic inheritance | Epidermal growth factor | Gliomas | Actin | Analysis | Genetic engineering | Cellular signal transduction | Biotechnology | Phosphorylation | Laboratories | Anti-oncogenes | Brain tumors | Brain cancer | Activation | Genomes | Malignancy | Kinases | Cancer therapies | Proteins | Cell activation | Glioma cells | Inhibition | Bioinformatics | Epidermal growth factor receptors | Gene expression | Amplification | Correlation analysis | Medical prognosis | Cell lines | Epigenetics | Tumor suppressor genes | Transduction | Mutation | Binding sites | Index Medicus
Journal Article
International Journal of Oncology, ISSN 1019-6439, 9/2015, Volume 47, Issue 3, pp. 849 - 856
Journal Article
Cancer Cell International, ISSN 1475-2867, 09/2015, Volume 15, Issue 1, pp. 91 - 91
Purpose: AKT plays a pivotal role in the signal transduction of cancer cells. MK2206, an AKT inhibitor, has been shown to be an effective anti-cancer drug to a... 
mTOR | MK2206 | Cell growth | Akt | Neuroblastoma | PDK1 | SOLID TUMORS | PI3K/AKT/MTOR INHIBITORS | KINASE INHIBITOR | PROTEIN-KINASES | BREAST-CANCER | DUAL MTORC1 | IN-VITRO | ONCOLOGY | ALLOSTERIC AKT INHIBITOR | MK-2206 | CARCINOMA | Cell proliferation | Complications and side effects | Care and treatment | Analysis | Cellular signal transduction | Research
Journal Article
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, ISSN 1078-1439, 03/2015, Volume 33, Issue 3
Objectives: To improve conventional chemotherapeutic efficacy, it is important to detect new molecular markers for chemosensitivity and possible accelerating... 
Urothelial cancer | BLADDER-CANCER | ACTIVATION | PROTEIN-KINASE | INHIBITOR MK-2206 | Akt pathway | LUNG-CANCER CELLS | Cisplatin | Invasion | BREAST-CANCER | HEPATOCELLULAR-CARCINOMA | ONCOLOGY | RESISTANCE | UROLOGY & NEPHROLOGY | MK2206 | CHEMORESISTANCE | CELLULAR-SURVIVAL
Journal Article